CAD-1005 (formerly VLX-1005)

July 13, 2026: Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported late-breaking Phase 2 clinical data for CAD-1005 (formerly VLX-1005), a first-in-class 12-lipoxygenase (12-LOX) inhibitor being developed for heparin-induced thrombocytopenia (HIT), presented as a late-breaking oral presentation at the ISTH 2026 Congress in Paris. The company said this was the first randomized, blinded, placebo-controlled clinical trial in HIT.

Phase 2 highlights presented: CAD-1005 showed an absolute reduction of more than 25% in new or worsening thrombotic events versus placebo (50% vs. >75%) when added to standard anticoagulation; the study was not powered for statistical significance. Safety signals included no serious adverse events attributed to CAD-1005, no major bleeding in SRA+ patients, and no deaths; fewer thromboembolic events were reported without an increase in major bleeding.

The presentation also suggested platelet count recovery is an inadequate surrogate endpoint, informing design for an upcoming pivotal Phase 3 registration trial. CAD-1005 has FDA Orphan Drug and Fast Track designations and EMA Orphan Drug status. The company also referenced partnering opportunities for CAD-1005 and tecarfarin.